Prevents the patient from travelling when feeling weak or disoriented
Moreover, KO mice for liver IGF-1 gene developed muscle insulin resistance (it is important to mention that skeletal muscle myocytes express high number of IGF-1R), showing an increase in insulin concentrations and a substantial decrease in the insulin-induced autophosphorylation of the insulin receptor and IRS in skeletal muscle (being normal in liver and white adipose tissue)
AOD-9604: Direct Lipolysis Theory AOD-9604 is a modified C-terminal fragment of human growth hormone, designed to isolate GH's fat-metabolizing properties: Lipolysis Activation: Theorized to stimulate fat breakdown through beta-3 adrenergic receptor pathways No IGF-1 Stimulation: Unlike full GH, AOD-9604 does not elevate insulin-like growth factor 1 Non-diabetogenic: Does not impair glucose metabolism or insulin sensitivity No Anabolic Effects: Does not promote muscle or organ growth Semaglutide: Central Regulation Theory Semaglutide achieves weight loss through systemic metabolic regulation: Hypothalamic Appetite Control: GLP-1 receptors in the brain reduce hunger and food-seeking behavior Gastric Emptying: Slowed stomach emptying promotes early satiety Insulin Optimization: Glucose-dependent insulin secretion improves metabolic efficiency Reward Pathway Modulation: Reduced hedonic eating and food reward responses The fundamental difference: AOD-9604 attempts to "burn" existing fat directly, while Semaglutide reduces caloric intake through appetite and satiety mechanisms, creating an energy deficit that leads to fat loss
B12 injections help those who dont have enough of this vitamin
Beyond the Injection: A Holistic Approach Injections work best as part of a broader health plan
Tesamorelin: the strongest clinical evidence for visceral fat Tesamorelin is the only peptide with FDA approval for reducing abdominal fat
